What is Tesamorelin?
Tesamorelin is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) that is FDA-approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. It's the only GHRH peptide with FDA approval.
Key Facts
- Brand name: Egrifta
- Type: GHRH analog (44 amino acids)
- FDA status: Approved for HIV lipodystrophy
- Unique benefit: Specifically targets visceral fat
How Tesamorelin Works
Mechanism
- Binds to GHRH receptors in pituitary
- Stimulates GH synthesis and release
- Increases IGF-1 levels
- Promotes lipolysis (fat breakdown)
- Particularly effective on visceral fat
Why Visceral Fat Specifically?
- Visceral fat is metabolically active
- More responsive to GH than subcutaneous fat
- Contains more GH receptors
- Clinical trials show selective reduction
Benefits of Tesamorelin
Primary: Visceral Fat Reduction
Clinical trials demonstrate:
- Average 15-18% reduction in trunk fat
- Maintained over 52 weeks
- Targets the most dangerous fat type
- Improves waist-to-hip ratio
Secondary Benefits
- Improved lipid profiles
- Better insulin sensitivity
- Reduced liver fat
- Potential cognitive benefits
- Improved body image
Dosing Protocol
FDA-Approved Dosing
| Parameter | Specification |
|---|---|
| Dose | 2mg daily |
| Timing | Once daily |
| Administration | Subcutaneous |
| Duration | Ongoing while benefit continues |
Important Considerations
- Consistent daily timing
- Rotate injection sites (abdomen)
- Allow refrigerated solution to warm slightly
- Empty stomach may enhance absorption
Who Can Benefit
FDA-Approved Use
- HIV patients with lipodystrophy
- Excess trunk fat accumulation
- Looking to reduce visceral adiposity
Potential Off-Label Considerations
- Metabolic syndrome with central obesity
- Those with stubborn visceral fat
- When lifestyle changes insufficient
Not Recommended For
- Active malignancy
- Pregnancy/breastfeeding
- Hypersensitivity to tesamorelin or mannitol
- Disruption of pituitary stalk
Side Effects
Common
| Effect | Frequency |
|---|---|
| Injection site reactions | 35% |
| Joint pain | 17% |
| Pain in extremity | 13% |
| Peripheral edema | 12% |
| Muscle pain | 11% |
Management Strategies
- Rotate injection sites
- Massage injection area gently
- OTC pain relievers for discomfort
- Usually improve over time
Serious (Rare)
- Hypersensitivity reactions
- Fluid retention issues
- Potential tumor growth (theoretical)
Tesamorelin vs. Other GH Peptides
| Feature | Tesamorelin | CJC-1295 | Sermorelin |
|---|---|---|---|
| FDA approved | Yes | No | Previously |
| Visceral fat focus | Strong | Moderate | Moderate |
| Dosing | Daily | Multiple/day | Daily |
| Cost | Higher | Lower | Lower |
| Research | Extensive | Growing | Moderate |
Why Choose Tesamorelin
- FDA-approved quality
- Strongest evidence for visceral fat
- Established safety profile
- Once-daily convenience
Clinical Trial Results
Phase 3 Trials
- 15.2% reduction in trunk fat (vs. 5.0% placebo)
- Maintained at 52 weeks
- Improvements in patient-reported distress
- No significant adverse effects on glucose
Long-Term Data
- Benefits maintained with continued use
- Fat regain if discontinued
- Safe for extended use
- Periodic reassessment recommended
Practical Considerations
Cost
- Brand name (Egrifta) is expensive
- May require prior authorization
- Specialty pharmacy distribution
- Research versions available
Monitoring
- Baseline and periodic IGF-1 levels
- Glucose monitoring
- Lipid panels
- Body composition assessment
Frequently Asked Questions
Q: How long until I see results?
A: Measurable changes in 12-26 weeks; visible changes may take 3-6 months.
Q: Will the fat come back if I stop?
